Molbio Diagnostics Aims for ₹940 Crore Through IPO to Boost Growth

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is set to launch an initial public offering (IPO) aiming to raise ₹940 crore. The funds will be divided between a fresh issue of ₹200 crore for capital expenditures and ₹740 crore through an offer for sale, which will reduce the promoter group's stake from 46.6% to 43%. This strategic move is designed to support the company's ambitious growth plans.

Capital Expansion and Market Reach

The company, which began operations in 2000, has established a significant footprint with six manufacturing sites across India. Molbio Diagnostics provides services to over 90 countries, including government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. Its flagship product, the 'Truenat' platform, offers rapid and accurate diagnostic solutions for over 30 diseases, including tuberculosis, which contributes significantly to its revenue.

Molbio's focus on expanding its capital expenditure is crucial for maintaining and enhancing its manufacturing capabilities to meet growing global demand. The IPO proceeds are expected to bolster this expansion, facilitating the company's efforts to innovate and improve its diagnostic offerings.

Financial Performance and Customer Base

Between FY24 and FY26, Molbio Diagnostics reported a 31.5% annual increase in revenue from operations, reaching ₹1,445.7 crore. The net profit saw a 40.2% rise, amounting to ₹164.1 crore. The company's EBITDA grew by 33.2% to ₹328.2 crore, with the EBITDA margin improving from 22% in FY24 to 22.6% in FY26.

A significant portion of Molbio's revenue, approximately 74%, comes from the sale of test kits, with tuberculosis diagnostics accounting for 70% of this segment. The company's reliance on a concentrated customer base, with top clients contributing over half of the revenue, highlights both an opportunity for stable income and a potential risk in terms of revenue diversification.

Valuation and Market Position

The IPO values Molbio Diagnostics at a price-earnings (P/E) multiple of up to 57, positioning it within a competitive range compared to other healthcare diagnostics and medical device companies in India, such as Poly Medicure and Dr. Lal PathLabs, which trade at P/E multiples between 54 and 81.

Molbio's strategic initiatives and robust financial performance make it an attractive option for investors with a high-risk appetite looking for long-term growth potential. However, the company's heavy reliance on tuberculosis test kits and a concentrated customer base could pose challenges that investors need to consider carefully.